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Abstract
Homozygous mutations in the glucocerebrosidase (GBA) gene result in Gaucher disease
(GD), the most common lysosomal storage disease. Recent genetic studies have revealed
thatGBAmutations confer a strong risk for sporadic Parkinson’s disease (PD). To investi-
gate howGBAmutations cause PD, we generated GBA nonsense mutant (GBA-/-) medaka
that are completely deficient in glucocerebrosidase (GCase) activity. In contrast to the peri-
natal death in humans and mice lacking GCase activity, GBA-/- medaka survived for
months, enabling analysis of the pathological progression.GBA-/- medaka displayed the
pathological phenotypes resembling human neuronopathic GD including infiltration of
Gaucher cell-like cells into the brains, progressive neuronal loss, and microgliosis. Detailed
pathological findings represented lysosomal abnormalities in neurons and alpha-synuclein
(α-syn) accumulation in axonal swellings containing autophagosomes. Unexpectedly, dis-
ruption of α-syn did not improve the life span, formation of axonal swellings, neuronal loss,
or neuroinflammation inGBA-/- medaka. Taken together, the present study revealed
GBA-/- medaka as a novel neuronopathic GD model, the pahological mechanisms of α-syn
accumulation caused by GCase deficiency, and the minimal contribution of α-syn to the
pathogenesis of neuronopathic GD.
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Author Summary
Parkinson’s disease (PD) is a neurodegenerative disease characterized by intraneuronal ac-
cumulation of alpha-synuclein (α-syn) called Lewy bodies and Lewy neurites. Recent ge-
netic studies have revealed that mutations in glucocerebrosidase (GBA), a causative gene of
Gaucher disease (GD), are a strong risk for PD. However, its pathological mechanisms
leading to PD remain largely unknown. Here, we generated GBA nonsense mutant
(GBA-/-) medaka which survive long enough for pathological analysis of disease progres-
sion. These mutant medaka display not only the phenotypes resembling human neurono-
pathic GD but also axonal accumulation of α-syn accompanied by impairment of the
autophagy-lysosome pathway. Furthermore, the present study demonstrates this α-syn ac-
cumulation has negligible contribution to the pathogenesis of neuronopathic GD in meda-
ka. GBA-/- medaka represent a valuable model for exploring the pathological mechanisms
of PD with GBAmutations as well as neuronopathic GD, and our findings have important
implications for the association of GBAmutations with PD.
Introduction
Gaucher disease (GD) is the most common lysosomal storage disease and is caused by homo-
zygous mutations in glucocerebrosidase (GBA). Mutations in GBA lead to decreased enzymatic
activity of glucocerebrosidase (GCase) and result in the accumulation of its substrates, gluco-
cerebroside and glucosylsphingosine[1,2]. GD is classically divided into three subtypes: a non-
neuronopathic form (type 1), an acute neuronopathic form (type 2), and a subacute neurono-
pathic form (type 3). Visceral manifestations of all forms are characterized by hepatosplenome-
galy, cytopenia, and skeletal disease. Pathologically, the accumulation of lipid-laden
macrophages, called Gaucher cells, are observed in the affected organs. Neurological manifesta-
tions of neuronopathic forms include brainstem dysfunction, intellectual disability, seizures,
and myoclonic movement. Pathological features of neuronopathic forms are neuronal loss,
astrogliosis, microgliosis, and perivascular accumulation of Gaucher cells[3]. The most severe
neuronopathic form, called the perinatal lethal type, has also been reported[4]. Common pre-
sentations of patients with the perinatal lethal type are hydrops fetalis and congenital ichthyo-
sis. Almost no residual GCase enzymatic activity is found in these cases. Because currently
available therapies are ineffective for neurological manifestations, a strong demand exists for
elucidation of the pathological mechanisms and the development of novel therapies.
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder. GBA
has recently drawn considerable attention because heterozygous mutations in this gene confer
a high risk for sporadic PD[5,6]. In addition, patients with type 1 GD also have an increased
life-time risk of developing PD[7]. PD patients carrying GBAmutations show intraneuronal
accumulation of alpha-synuclein (α-syn) called Lewy bodies and Lewy neurites, which are the
pathological hallmarks of sporadic PD[3]. Several cellular, animal, and postmortem studies
have indicated an association between GBAmutations and α-syn accumulation. For example,
deficiency in GCase enzymatic activity causes lysosomal dysfunction and α-syn accumulation
[8,9,10,11,12]. Increased α-syn in turn creates a vicious cycle by inhibiting the trafficking of
GCase to lysosomes, thus leading to decreased GCase activity in lysosomes[9]. Consistent with
this notion, mouse models overexpressing α-syn and postmortem tissue from patients with PD
show reduced GCase activity in the brains[13,14,15]. Although several hypotheses have been
proposed, further mechanisms of how GBAmutations contribute to the development of PD
remain elusive.
α-synuclein Accumulation in Gaucher Disease Medaka
PLOS Genetics | DOI:10.1371/journal.pgen.1005065 April 2, 2015 2 / 22
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Medaka (Oryzias latipes) are a versatile vertebrate animal model for disease research. These
fish are easy to handle, have a relatively short generation time (2–3 months), produce a large
number of progeny per generation, and have several inbred strains[16]. Importantly, medaka
have an advantage as an animal model of PD due to endogenous α-syn in contrast to inverte-
brate models that lack α-syn. Moreover, several genetic manipulations can be performed in
medaka in addition to established transgenic techniques[17,18,19,20,21]. So far, we have re-
ported genetic PD models of medaka that develop locomotor dysfunction accompanied by the
selective loss of dopaminergic and noradrenergic neurons[22,23]. Considering these lines of ev-
idence, medaka have the potential to be a new animal model of PD.
Here, we generated GBA nonsense mutant medaka and found that homozygous GBA non-
sense mutant (GBA-/-) medaka are a viable neuronopathic GD model. GBA-/- medaka devel-
oped remarkable α-syn accumulation in the brains and thus provide novel insights into the
association of GBAmutations with α-syn accumulation. Furthermore, we revealed minimal
contribution of endogenous α-syn to the pathogenesis of neuronopathic GD in medaka.
Results
Generation ofGBA nonsense mutant medaka
We generated GBA nonsense mutant medaka to investigate the mechanisms by which GBAmu-
tation leads to PD. To identify medakaGBA orthologs, we searched the medaka genome database
(http://www.ensembl.org/Oryzias_latipes/Info/Index) with the basic local alignment search tool
and found only one ortholog of human GBA. We cloned the medakaGBAwith reverse transcrip-
tion-polymerase chain reaction (RT-PCR) and rapid amplification of cDNA ends and found that
this gene has 11 exons encoding a protein of 522 amino acids. The amino acid sequence of meda-
kaGBA showed 53% homology to that of human GBA (S1 Fig). Next, we screened a targeting-
induced local lesions in genome (TILLING) library for medaka GBA using a high-resolution
melting assay[17,24]. We identified a nonsense mutant (W337X) and generated the nonsense
mutant medaka by in vitro fertilization (Fig. 1A). We examined GCase activity in the brains of
GBAmutants after crossing with heterozygous mutants. GBAW337X/W337X (GBA-/-) medaka
showed complete deficiency in GCase activity, and GBAWT/W337X (GBA+/-) medaka showed a de-
crease in GCase activity of about 50% compared to wild-type (GBA+/+) medaka (Fig. 1B). Al-
though humans and mice lacking GCase activity die soon after birth[4,25,26], GBA-/- medaka
survived for more than 3 months, enabling us to analyze the pathological progression (Fig. 1D).
GBA-/- medaka showed abnormal rotating swimming movement at 2 months (S1, S2 Movie) and
the abnormal appearance of a bent spine at 3 months (Fig. 1C). High levels of glucocerebroside
accumulated in the brains ofGBA-/- medaka (Fig. 1E), whereas the amount of galactocerebroside,
an isomer of glucocerebroside, was not changed. Glucocerebroside with C18 fatty acids was the
most dominant type in the brains of GBA-/- medaka (S2 Fig), an observation that is consistent
with the neuronopathic GDmouse model[27].
GBA-/- medaka showed neuronopathic GD-like pathology
We performed pathological analyses of GBA-/- medaka. Patients with GD show Periodic acid-
Schiff-positive Gaucher cells in affected visceral organs such as the liver, spleen, and bone mar-
row, whereas GBA-/- medaka showed abnormal Periodic acid-Schiff-positive cells in the spleen
and kidney, but not in the liver, at 3 months (S3 Fig). Next, we examined the brains of GBA-/-
medaka and found abnormal cells with large vacuoles mainly in the periventricular gray zone
of the optic tectum (Fig. 2A, B). Transmission electron microscopy revealed that these cells
were macrophage-like and had large vacuoles containing filamentous structures (Fig. 2C). Sim-
ilar filamentous structures are observed in Gaucher cells of patients with GD and mouse
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models of GD[26,28,29]. The staining intensity with Luxol fast blue was decreased, and single-
stranded DNA (ssDNA)-positive cells were observed inGBA-/- medaka (Fig. 2D), indicating my-
elin loss and cell death, respectively. In situ hybridization for apolipoprotein E (APOE), a micro-
glial marker in teleost fish[30], revealed proliferating activated microglia in GBA-/- medaka
(Fig. 2D). Teleost fish have glial fibrillary acidic protein (GFAP)-expressing radial glial cells (or
ependymoglial cells) instead of astrocytes as in mammals[31]. Humans and mice with neurono-
pathic GD show astrogliosis in their brains[3,32], whereas neither proliferation of GFAP-positive
radial glial cells nor elevated levels of GFAP were observed inGBA-/- medaka (Fig. 2D, E). To in-
vestigate the type of neuronal cells that die inGBA-/- medaka, we counted the numbers of tyro-
sine hydroxylase (TH)-positive dopaminergic neurons in the middle diencephalon, which
corresponds to the human substantia nigra[33], TH-positive noradrenergic neurons in the locus
coeruleus, and tryptophan hydroxylase (TPH)-positive serotonergic neurons in the superior
raphe at 2 and 3 months. GBA-/- medaka showed progressive cell loss of all these neurons
(Fig. 2F). Consistent with these findings, the amount of TH was decreased inGBA-/- medaka
(Fig. 2G). Collectively,GBA-/- medaka exhibited neuronopathic GD-like pathology including
progressive and non-selective neuronal loss.
GBA-/- medaka developed α-syn accumulation in axonal swellings
containing autophagosomes
Medaka express α-syn, which is a protein consisting of 127 amino acids. To investigate α-syn
pathology in GBA-/- medaka, we created a medaka α-syn antibody against the epitope of amino
acids 90 to 104 (S4A Fig). Medaka also express β-synuclein, γ-synuclein-a, and γ-synuclein-b
in addition to α-syn, but these other synucleins do not have amino acid sequences homologous
to the epitope of the medaka α-syn antibody (S4B Fig). Next, we generated α-syn deletion
Fig 1. Generation ofGBA nonsensemutant medaka. (A) Upper panel: DNA and amino acid sequences ofGBA nonsense mutant medaka. Lower panels:
Sequence data for each genotype. A = green, T = red, G = black, and C = blue. (B) Relative GCase activity in medaka brains (n = 10). (C) Abnormal posture
(‘bent spine’) inGBA-/- medaka at 3 months. (D) Survival curves for each genotype. PFD, post-fertilization day. (E) Quantification of glucocerebroside and
galactocerebroside in medaka brains at 3 months with SFC/MS/MS (n = 3–4). For all analyses, data are the mean ± standard error of the mean (SEM). n.s.
means not significant.
doi:10.1371/journal.pgen.1005065.g001
α-synuclein Accumulation in Gaucher Disease Medaka
PLOS Genetics | DOI:10.1371/journal.pgen.1005065 April 2, 2015 4 / 22
Fig 2. Pathological analyses ofGBA-/- medaka. (A) Schematic of a lateral view of the medaka brain. Each number signifies a part of the brain. 1:
telencephalon, 2: optic tectum, 3: diencephalon, 4: cerebellum, 5: medulla oblongata. The brain sections used for pathological analyses in the present study
are illustrated by the vertical line. (B) Hematoxylin and eosin staining. Abnormal cells observed in the periventricular gray zone of the optic tectum
(arrowhead) inGBA-/- medaka at 3 months. Scale bars, 50 μm. Right panel: High-magnification image showing abnormal cells with large vacuoles (arrows).
Scale bar, 5 μm. (C) Transmission electron micrographs showing abnormal macrophage-like cells. Left panel: A whole-cell image of an abnormal
macrophage-like cell. Dashed lines outline a whole abnormal cell. N, Nucleus. Scale bar, 2 μm. Right panel: High-magnification image of filamentous
structures in vacuoles. Scale bar, 500 nm. (D) Klüver-Barrera (KB) staining, ssDNA immunohistochemistry, APOE in situ hybridization, and GFAP
immunohistochemistry in the diencephalon. Commissura posterior with decreased Luxol fast blue staining intensity (arrowhead) and ssDNA-positive dead
cells (arrows) inGBA-/- medaka. APOE in situ hybridization revealed proliferating activated microglia inGBA-/- medaka. The staining intensity and area of
GFAP were not changed inGBA-/- medaka. Scale bars, 50 μm. (E) Western blot analysis of GFAP and β-actin. The expression level of GFAP was not
changed among genotypes. (F) Number of TH-positive neurons in the middle diencephalon, number of TH-positive neurons in the locus coeruleus, and
number of TPH-positive neurons in the superior raphe at 2 and 3 months. InGBA-/- medaka, progressive neuronal loss was observed in all types of neurons
(n = 4–6, *p< 0.05, ***p< 0.001). (G) Western blot analysis of TH and β-actin (n = 7, *p< 0.05, **p< 0.01). For all analyses, data are the mean ± SEM.
doi:10.1371/journal.pgen.1005065.g002
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mutant medaka using TALENs. Deletion of 11 bases near the start codon in α-syn resulted in a
frame shift mutation (S4C Fig). Wild-type, heterozygous, and homozygous α-syn deletion mu-
tant (α-syn+/+, α-syn+/-, and α-syn-/-, respectively) medaka could be distinguished with PCR anal-
ysis of α-syn (S4D Fig). RT-PCR analysis of α-synmRNA revealed that α-syn-/- medaka did not
express intact α-synmRNA (S4E Fig). Western blot analysis with the medaka α-syn antibody
revealed a 14-kDa band, which was specifically found in α-syn+/+medaka (S4F Fig). The authen-
ticity of the antibody was confirmed by the lack of immunostaining with the medaka α-syn anti-
body in the brains of α-syn-/- medaka (S4G Fig). Consistent with the findings in mammals,
medaka α-syn was mainly found presynaptically with immunoelectron microscopy (S4H Fig).
Then, we performed immunohistochemical analysis and found abundant α-syn accumula-
tion in the brains of GBA-/- medaka at 3 months (Fig. 3A). α-syn accumulation was also ob-
served at 2 months, but not at 1 month (S5 Fig). Abnormal structures observed with toluidine
blue staining were similar to α-syn accumulations in size and distribution (Fig. 3A). Transmis-
sion electron microscopy revealed numerous axonal swellings containing vacuoles and other
various materials in the brains of GBA-/- medaka (Figs. 3B, S6A). A considerable number of
these vacuoles had double membranes and sometimes contained mitochondria, suggesting that
these vacuoles were autophagosomes. Consistent with this, LC3, an autophagosomal marker,
accumulated in the brains of GBA-/- medaka (Fig. 3A). Moreover, immunogold-labeled α-syn
was detected in axonal swellings with immunoelectron microscopy (Fig. 3C). Conventional
and confocal double immunofluorescence microscopy revealed that accumulated α-syn coloca-
lized with LC3 accumulations (Fig. 3D), and a considerable portion of the α-syn signals in axo-
nal swellings colocalized with LC3 signals (Figs. 3E, S6B). In addition to these findings,
ubiquitin also accumulated in α-syn-positive axonal swellings (Figs. 3E, S6B). To examine the
α-syn expression level and solubility, we performed sequential biochemical fractionation as-
says. The total amount of α-syn in the Triton-soluble fraction was not increased in GBA-/- me-
daka. However, when adjusted for the amount of neuron-specific enolase (NSE) and
considering the robust neuronal loss in GBA-/- medaka, α-syn was significantly increased in
GBA-/- medaka (Fig. 3F). The decreased amount of neurofilament also reflected the neuronal
loss in GBA-/- medaka (Fig. 3F). No apparent α-syn band was detected in the Triton-insoluble,
SDS-soluble fraction in all genotypes. In agreement with the accumulation of autophagosomes
in axonal swellings, the ratio of LC3-II to LC3-I was increased in GBA-/- medaka (Fig. 3F).
Meanwhile, we also investigated the phenotypes of GBA+/- medaka because heterozygous
mutations in GBA are a strong risk for PD[5,6]. However, GBA+/- medaka even at 12 months
did not show any apparent abnormal phenotypes including α-syn pathology, the numbers of
TH-positive neurons, swimming movement, or the amounts of several neurotransmitters
(S7A–S7E Fig).
Impairment of the autophagy-lysosome pathway in neurons ofGBA-/-
medaka
Previous studies of GDmouse models reported that p62/SQSTM1 (an autophagic substrate) ac-
cumulates in neurons and astrocytes[34], and the number of Cathepsin D-positive puncta is de-
creased in neurons[35]. These observations prompted us to examine the autophagy-lysosome
pathway in GBA-/- medaka. Immunohistochemical analysis revealed that ubiquitin- and p62-
positive aggregates were observed mainly in the perikarya of neurons (Figs. 4A, D, S8B). These
aggregates were observed only in neurons and not in GFAP-positive radial glial cells or Lycoper-
sicon Esculentum (Tomato) Lectin (LEL)-positive microglia (S8A Fig). LEL is an excellent tele-
ost microglial marker[36]. Western blot analysis showed that the amounts of ubiquitin and p62
were increased in the brains of GBA-/- medaka (Fig. 4C). In contrast, these aggregates did not
α-synuclein Accumulation in Gaucher Disease Medaka
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Fig 3. Axonal swellings with α-syn accumulation inGBA-/- medaka. (A) α-syn and LC3 immunohistochemistry, and toluidine blue staining in the
diencephalon at 3 months. Left panels: α-syn accumulations were observed inGBA-/- medaka. Scale bars, 50 μm. Other panels: outlined area of left panels.
The distribution of α-syn accumulations was similar to that of abnormal structures observed with toluidine blue staining and LC3 accumulations (arrowheads).
Scale bars, 20 μm. (B) Transmission electron micrographs of axonal swellings inGBA-/- medaka. Left panel: a swelling of a myelinated axon containing
vacuoles and electron-dense bodies. Right panel: vacuoles in an axonal swelling containing mitochondria (arrows). Scale bars, 500 nm. (C) Immunoelectron
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colocalize with LC3 accumulations or Cathepsin D-positive organelles (Figs. 4D, S8B). These or-
ganelles, which are putative lysosomes, showed decreased Cathepsin D staining intensity and
abnormal morphology (Fig. 4A). Consistent with this, neurons that contained lysosome-like or-
ganelles filled with filamentous structures were observed with transmission electron microscopy
(Fig. 4B).
The phenotypes ofGBA-/- medaka were rescued by transgenic
expression ofGBA
GBA nonsense mutant medaka have random point mutations in the genome at loci other than
GBA. Therefore, we performed a rescue experiment to determine whether the abnormal phe-
notypes observed in GBA-/- medaka were really caused by GBAmutation. We created medaka
GBA-expressing vectors driven by a medaka growth-associated protein 43 (GAP-43) promoter
(S9A Fig)[37]. GAP-43mRNA is expressed mainly in nervous system in medaka[37]. We es-
tablished six medaka GBA transgenic lines (Tg(GAP-43:GBA)) using these vectors and crossed
them with GBA nonsense mutant medaka. Each line of GBA-/- medaka with GBA transgene
(Tg(GAP-43:GBA);GBA-/-) showed GCase activity of various levels in the brains at 3 months
(S9B Fig). All lines of Tg(GAP-43:GBA);GBA-/- medaka showed normal swimming movement
at 2 months (S3 Movie). Also, the swimming distance was increased in Tg(GAP-43:GBA)line3;
GBA-/- medaka (S9C Fig). Pathological analysis of the brains of Tg(GAP-43:GBA)line3;GBA-/-
medaka including hematoxylin and eosin staining, in situ hybridization for APOE, and immu-
nohistochemistry for p62 and α-syn revealed no apparent abnormality (S9D Fig). We conclud-
ed that the abnormal phenotypes observed in the brains of GBA-/- medaka were caused by the
GBAmutation.
Disruption of α-syn inGBA-/- medaka did not improve the phenotypes
Many studies have reported that accumulated α-syn caused by α-syn overexpression results in
neurotoxicity[38]. Neuroinflammation is observed in the brains of patients with PD, and much
evidence shows that neuroinflammation promotes disease progression[39]. Moreover, a recent
study reported that oligomeric α-syn released from neurons activates inflammatory responses
in microglia[40].
We examined the toxicity of α-syn in GBA-/- medaka by crossing GBA nonsense mutant
medaka with α-syn deletion mutant medaka. α-syn-/- medaka showed no apparent abnormal
phenotypes in their outer appearance, swimming movement, or life span like α-syn-disrupted
mice[41]. The life spans of GBA-/-α-syn+/- and GBA-/-α-syn-/- medaka were not prolonged com-
pared to that of GBA-/-α-syn+/+ medaka (Fig. 5A). Moreover, the number of LC3-positive
puncta was not changed in GBA-/-α-syn-/- medaka, indicating that α-syn was not primarily in-
volved in formation of axonal swellings (Fig. 5B). The numbers of dopaminergic neurons in
the middle diencephalon and noradrenergic neurons in the locus coeruleus were not changed
in either GBA-/- α-syn+/- or GBA-/- α-syn-/- medaka (Fig. 5C). We also examined the extent of
neuroinflammation with in situ hybridization for APOE and quantitative RT-PCR for tumor
necrosis factor (TNF)αmRNA. The number of APOE-positive cells and the expression level of
micrograph of an axonal swelling in aGBA-/- medaka with immunogold-labeled α-syn. Dashed lines outline an axonal swelling containing vacuoles and
electron-dense bodies. The boxed area is enlarged in the inset. Scale bar, 500 nm. (D) Double immunostaining for LC3 (green) and α-syn (red) inGBA-/-
medaka. Nuclei were visualized with DAPI (blue). α-syn accumulations colocalized with LC3 accumulations (arrowheads). Scale bar, 20 μm. (E) Conforcal
microscope images of α-syn-positive axonal swellings. Upper panels: Double immunostaining for LC3 (green) and α-syn (red). A considerable portion of the
α-syn signals colocalized with LC3 signals. Lower panels: Double immunostaining for ubiquitin (green) and α-syn (red). Ubiquitin colocalized with an α-syn
accumulation. Scale bars, 5 μm. (F) Western blot analysis of α-syn, LC3, β-actin, NSE, and neurofilament at 3 months (n = 6–7, *p< 0.05, **p< 0.01). For
all analyses, data are the mean ± SEM.
doi:10.1371/journal.pgen.1005065.g003
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Fig 4. Impairment of the autophagy-lysosome pathway inGBA-/- medaka. (A) Ubiquitin, p62, and Cathepsin D immunohistochemistry in the neuronal
layer of the optic tectum at 3 months. Almost all of the cells in these figures are neurons. Ubiquitin-positive and p62-positive aggregates were observed in the
perikarya of neurons inGBA-/- medaka at 3 months (arrowheads). Morphologically abnormal organelles with decreased Cathepsin D staining intensity were
observed inGBA-/- medaka (arrows). Scale bars, 10 μm. (B) Transmission electron micrographs of neurons. Left panel: Neuron of aGBA+/+medaka.
Electron-dense organelles (arrows) are likely lysosomes. N, Nucleus. Scale bar, 2 μm. The inset shows a high-magnification image of electron-dense
organelles. Scale bar, 500 nm. Middle panel: Neuron of aGBA-/- medaka. An aggregate containing filamentous structures (arrowhead) is continuous with an
electron-dense organelle. N, Nucleus. Scale bar, 2 μm. Right panel: High-magnification image of an aggregate of filamentous structures (arrowhead) and
electron-dense organelles (arrows) in aGBA-/- medaka. Scale bar, 500 nm. (C) Western blot analysis of ubiquitin, p62, and β-actin (n = 4–7, *p< 0.05,
α-synuclein Accumulation in Gaucher Disease Medaka
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TNFα were not changed (Fig. 5D, E). Collectively, we found no evidence for α-syn involvement
in the short life span, formation of axonal swellings, dopaminergic and noradrenergic neuronal
loss, and neuroinflammation that are observed in GBA -/-medaka.
Discussion
To date, several genetic animal models of neuronopathic GD including mouse, dog, and sheep
have been reported[42]. Gba null mice die within 24 hours of birth due to permeability barrier
***p< 0.001). (D) Conforcal microscope images ofGBA-/- medaka. Upper panels: ubiquitin (green) and p62 (red). p62-positive aggregates colocalized with
ubiquitin-positive aggregates (white arrowheads). Middle panels: LC3 (green) and p62 (red). p62-positive aggregates (yellow arrows) did not colocalize with
LC3 accumulations (yellow arrowheads). Lower panels: Cathepsin D (green) and p62 (red). p62-positive aggregates did not colocalize with Cathepsin D-
positive organelles. Nuclei were visualized with DAPI (blue). Scale bars, 10 μm. For all analyses, data are the mean ± SEM.
doi:10.1371/journal.pgen.1005065.g004
Fig 5. Disruption of α-syn did not change the pathological phenotypes inGBA-/- medaka. (A) Survival curves for each genotype. Life spans were not
changed among genotypes. (B) α-syn and LC3 immunohistochemistry in the diencephalon. α-syn accumulations were observed only inGBA-/-α-syn+/+
medaka (arrows). The number of LC3-positive puncta was not different betweenGBA-/-α-syn+/+ andGBA-/-α-syn-/- medaka (arrowheads). Scale bars, 20 μm.
(C) Number of TH-positive neurons in the middle diencephalon and the locus coeruleus at 3 months (n = 6). (D) Upper panel: APOE in situ hybridization in the
optic tectum and the diencephalon. Lower panel: The number of APOE-positive cells per section (n = 9). Scale bars, 50 μm. (E) Quantification of TNFαmRNA
levels normalized to β-actinmRNA in medaka brains with quantitative RT-PCR (n = 8). For all analyses, data are the mean ± SEM.
doi:10.1371/journal.pgen.1005065.g005
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defects in the skin[26,43]. Thus, conditional knockout K14-lnl/lnl mice with normal GCase ac-
tivity in their skin were generated[27]. However, use of these mice is limited because they sur-
vive only 2 weeks after birth. Mice harboring a Gbamissense mutation combined with
prosaposin- or saposin C-deficient mice, another neuronopathic GD model, also show neuro-
nopathic abnormalities[29,34] and have the advantage of longer survival than K14-lnl/lnl mice.
However, the relevance of these mice to neuronopathic GD is controversial. The present study
revealed that GBA-/- medaka survive long enough for pathological analysis of disease progres-
sion. As an example, GBA-/- medaka showed α-syn accumulation at 2 months, not at 1 month
after fertilization. Considering these observations, GBA-/- medaka are useful as a viable neuro-
nopathic GD model with endogenous α-syn accumulation.
GBA-/- medaka showed several phenotypes different from those of mammalian neurono-
pathic GD model. Firstly, the skin of GBA-/- medaka looks intact whereas severe skin lesion is
observed in patients with perinatal lethal type GD and Gba null mice[4,43]. Secondly, GBA-/-
medaka exhibited PAS-positive abnormal cells in spleen and kidney which presumably corre-
spond to human Gaucher cells. In patients with GD, Gaucher cells are not found in kidney, but
in liver, spleen and bone marrow. These differences could be explained by the fact that in adult
teleost fish kidney has hematopoietic function instead of mammalian bone marrow[44]. Lastly,
the proliferation of GFAP-positive radial glial cells was not observed in GBA-/- medaka whereas
astrogliosis is observed in humans and mice with neuronopathic GD. It was reported that the
reaction of GFAP-positive radial glial cells to inflammation is different from that of mammali-
an astrocytes[31].
Lysosomes play a fundamental role in the autophagic pathway by fusing with autophago-
somes and digesting their contents[45]. In general, lysosomal dysfunction results in defective
digestion and accumulation of autophagic substrates such as polyubiquitinated proteins, p62,
and dysfunctional mitochondria, accompanied by accumulation of autophagosomes. Axonal
swellings containing autophagosome-like structures are observed in mouse models of lysosom-
al storage diseases such as neuronopathic GD mice, Niemann-pick type C1 mice, Cathepsin D-
deficient mice, and Cathepsin B/L double-deficient mice[34,46,47]. A previous study reported
that autophagosomes are formed in the distal part of the axon and undergo retrograde trans-
port toward the cell body[48]. Another previous study demonstrated that inhibition of lyso-
somal function in primary neurons from mouse embryos disrupts the axonal transport of
autophagosomes and causes their accumulation in axons[49]. Considering these lines of evi-
dence, we propose that GCase deficiency primarily causes lysosomal dysfunction, leading to
disrupted retrograde transport of autophagosomes in axons and formation of axonal swellings
with α-syn accumulation (Fig. 6). Contrary to our expectations, p62-positive aggregates did
not colocalize with LC3- and α-syn-positive axonal swellings, but were mainly located in the
perikarya of neurons. These results suggest the possibility that presynaptic α-syn is transported
proximally and degraded in a p62-independent autophagy-lysosome pathway. A previous
study supports this hypothesis. Conditional knockout mice lacking ATG7 in TH-positive neu-
rons show α-syn aggregates in swollen axons in the striatum, but not in cell bodies in the mid-
brain, indicating that autophagic dysfunction initially causes α-syn aggregates in the distal part
of axons[50]. In addition, another previous study demonstrated that α-syn aggregation occurs
earlier in axons than in neuronal cell bodies in the cardiac sympathetic nervous system in PD
patients[51]. Because axonal retrograde transport may be involved in the degradative pathway
of α-syn and may be a therapeutic target in PD, further studies are required to elucidate the
precise mechanisms.
Because GBA+/- medaka as old as 12 months did not show any apparent abnormal pheno-
types, we could not directly investigate how heterozygous GBAmutations cause PD. Mean-
while, according to a recent report, induced pluripotent stem cell-derived neurons from PD
α-synuclein Accumulation in Gaucher Disease Medaka
PLOS Genetics | DOI:10.1371/journal.pgen.1005065 April 2, 2015 11 / 22
patients carrying heterozygous GBAmutations show α-syn accumulation, an impaired autop-
hagy-lysosome pathway, and dysregulation of calcium homeostasis[12]. The reason for differ-
ences in phenotypes between in vivo and in vitromodels is unclear. However, our findings
from GBA+/- medaka seem to be reasonable because the penetrance of PD in GBAmutation
carriers is estimated to be at most 30% by the age of 80 years[52]. Thus, second hits such as en-
vironmental factors and other genetic factors are probably required for the development of PD
pathology in vivo.
Cellular and animal PD models overexpressing α-syn have provided evidence for the vari-
ous potential toxic mechanisms of α-syn. However, few studies have demonstrated the patho-
logical role of endogenous α-syn in vivo, which may reflect the authentic role for α-syn in PD.
A previous study showed that α-syn null mice are resistant to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) toxicity compared with wild-type mice[53]. However, it is unclear
whether this improvement is due to attenuation of α-syn toxicity or α-syn-mediated changes
in the presynaptic machinery. Another previous study showed that the formation of intraneur-
onal inclusions and neurodegeneration in 26S proteasome-depleted mice is independent of α-
syn[54]. In the present study, disruption of α-syn did not improve the life span, neuronal loss,
or neuroinflammation in GBA-/- medaka. Moreover, α-syn was not involved in the accumula-
tion of autophagosomes in axons. Our data indicate that α-syn accumulation is a downstream
event, and other severe pathological factors may obscure the involvement of α-syn in the path-
ogenesis of neuronopathic GD in medaka.
In summary, the present study showed that GBA-/- medaka are useful as a viable neurono-
pathic GDmodel with endogenous α-syn accumulation. Long-term survival of these fish allows
us to observe the pathological progression. Our data revealed that GCase deficiency causes ly-
sosomal dysfunction in neurons and α-syn accumulation in axonal swellings containing
Fig 6. Pathological findings and proposed pathological mechanisms in neurons ofGBA-/- medaka.
Neurons ofGBA-/- medaka showed lysosomal dysfunction, which is reflected in morphologically abnormal
structures with decreased Cathepsin D staining intensity, and axonal swellings containing autophagosomes
where α-syn and ubiquitin accumulate. p62-positive aggregates, which colocalize with ubiquitin, are not
located in axonal swellings, but presumably in soma or dendrites. Considering the previous studies about the
axonal transport of autophagosomes, we propose that GCase deficiency primarily causes lysosomal
dysfunction, which leads to disrupted retrograde transport of autophagosomes in axons and formation of
axonal swellings with α-syn accumulation.
doi:10.1371/journal.pgen.1005065.g006
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autophagosomes. Axonal transport of α-syn may play an important role in the mechanisms of
GBAmutations leading to PD and may also be a therapeutic target in PD. Furthermore, we
demonstrate the minimal contribution of α-syn to the pathogenesis of neuronopathic GD in
medaka. GBA-/- medaka represent a valuable model for exploring the pathological mechanisms




Medaka were anesthetized in 0.02% tricaine in fish water and then sacrificed. All experimental
procedures used in this study followed national guidelines. The Animal Research Committee
of Kyoto University granted a formal waiver of ethical approval and also granted permission.
Maintenance of medaka
Medaka of the Kyoto-cab strain, a substrain of Cab, were maintained at 27°C in a recirculating
aquaculture system. Adult fish were kept in a reproduction regimen (14 hr light/10 hr dark).
Eggs were kept in a dark box at 28°C.
Cloning of medaka genes
RNA was extracted from wild-type medaka brains with Qiazol (QIAGEN) according to the
manufacturer’s instructions. cDNA was synthesized using the PrimeScript RT reagent kit (Per-
fect Real Time) (TaKaRa, #RR037A). To identify medaka GBA, SNCA, SNCGb, p62/SQSTM1,
andMAP1LC3B orthologs, we referred to the medaka genome database (http://www.ensembl.
org/Oryzias_latipes/Info/Index). Because their cDNA sequences and amino acid sequences
were not completely known, we determined their cDNA sequences using a combination of RT-
PCR and rapid amplification of cDNA ends, the products of which were generated using See-
gene’s Capfishing kit (Seegene). The cDNA sequences can be found in the European Nucleo-
tide Archive (ENA, accession numbers LM644999–645003).
Generation ofGBA nonsense mutant medaka
GBAmutant medaka were generated as described[17]. To find GBAmutations in the TILLING
library, we narrowed down mutated candidates from 5,771 samples using a high-resolution
melting assay, followed by determination of the DNA sequences[24]. We screened the TILL-
ING library for exons 1–2, exons 5–7, exon 8, and exons 9–11 of GBA. In vitro fertilization was
carried out using sperm from a sample with the favorable mutation. To genotype the progeny
of GBAWT/W337X mutants, PCR was performed with the following primer set (50-AGGGTTG
AAGGGGTTAAGCA-30, 50-TTGTAACCAGTACCGCAGCA-30), designed HybProbes (50-
LC Red 640-CATGTACCAGTGGACG-Phosphate-30, 50-CCTAAGCTTATATCTGCAGG
GACTAAACTGT-Fluorescein-30), and LightCycler 480 Probes Master in LightCycler 480
(Roche) according to the manufacturer's instructions. The genotypes can be distinguished with
high-resolution melting curve analysis. GBAWT/W337X mutants were back-crossed to Kyoto-
Cab medaka at least seven times and then crossed to obtain GBAW337X/W337X mutants.
Rescue experiment
For the rescue experiment, we established GBA transgenic medaka in which medaka GBA ex-
pression was driven by the medaka GAP-43 promoter (Tg(GAP-43:GBA)). We used an insula-
tor located in the upstream region of sea urchin (Hemicentrotus pulcherrimus) arylsulfatase
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[55,56]. The transgenic construct was flanked by two insulators and included the medaka
GAP-43 promoter followed by an internal ribosome entry site (IRES), enhanced GFP (EGFP),
and the Simian virus 40 polyadenylation site or the medaka β-actin 30-untranslated region
(30UTR) (S8A Fig). The medaka GAP-43 promoter contained a 1.0-kb fragment of the 50-
flanking region of the gene. A DNA fragment of the transgene was inserted into EcoR I/Sal I
restriction enzyme sites of the pDs-actb2k-EGFP plasmid. pDs-actb2k-EGFP was constructed
by inserting an Xho I/Spe I fragment from pactb2k-EGFP into the Xho I/Spe I site of the
pDs-GTDEL4 plasmid, which contains 50- and 30-Ds sequences[21,57]. The resultant vector
was injected into the cytoplasm of fertilized Kyoto-Cab eggs before the first cleavage
as described[20].
Generation of α-syn deletion mutant medaka
α-syn deletion mutant medaka were generated with TALENs as described[58]. To genotype the
progeny of α-syn deletion mutants, PCR was performed with the following primer set (50-
GATCCCGAGCCATCCAC-30, 50-TGCAACTGTGGAAACACCAT-30), followed by electro-
phoresis in a 10% (w/v) polyacrylamide gel (S4D Fig). RT-PCR for α-syn was performed with
the following primer sets (α-syn: 50-GATCCCGAGCCATCCAC-30, 50-TTTGGAGAAACCC
TTCATTAAC-30; β-actin: 50-TCCACCTTCCAGCAGATGTG-30, 50-AGCATTTGCGGTGG
ACGAT-30) (S4E Fig).
Behavioral analyses
The spontaneous swimming movement of medaka was traced using a video camera positioned
above the water tank and analyzed with ethovision XT 5 (Noldus). The water tank was a trans-
parent circular container (20 cm diameter, 2 cm water depth, room temperature). Image acqui-
sition began 5 min after medaka were placed in a new water tank. Data were collected
continuously for the subsequent 3 min.
GCase enzymatic activity assay
The assay for GCase enzymatic activity was performed as described[11]. Medaka brains were
homogenized in 40 μl sample buffer (10 mM Tris-HCl, 150 mMNaCl, 1% (v/v) Triton X-100,
pH 7.4), sonicated, and centrifuged at 10,000 ×g at 4°C for 5 min. Aliquots containing 50 μg
protein were incubated in assay buffer (5 mM 4-Methylumbelliferyl β-D-glucopyranoside
(Wako, #324–37441), 1% (w/v) sodium taurocholate (Wako, #197–10033), 50 mM sodium cit-
rate, 50 mM sodium phosphate, pH 5.0) in the presence or absence of 2 mM Conduritol B ep-
oxide (Toronto Research Chemicals, #C666000) in a total volume of 100 μl at 37°C for 4 hr.
The reaction was stopped by adding 100 μl of 0.4 M glycine, pH 10.8, and the fluorescence at
460 nm (emission 355 nm) was measured with Fluoroskan Ascent FL (Thermo Fisher).
Lipid analyses with supercritical fluid chromatography (SFC)/mass
spectrometry (MS)/MS
Medaka brains were stored at—80°C until analyses and homogenized in 1 ml tissue homogeni-
zation buffer (250 mM sucrose, 25 mM KCl, 50 mM Tris-HCl, 0.5 mM EDTA, pH 7.4). Ali-
quots containing 1 mg protein were used for the analyses. Levels of glucocerebroside and
galactocerebroside were measured with high-performance liquid chromatography-tandem MS
as described with modification using SFC separation[59].
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Generation of the medaka α-syn antibody
A synthetic peptide corresponding to amino acids 90–104 of medaka α-syn conjugated to Key-
hole Limpet Hemocyanin was used for immunization of rabbits. Serum was obtained 49 days
after immunization and purified with affinity chromatography.
Immunohistochemical analyses
Frozen and paraffin sections were used for immunohistochemical analyses. For frozen sections,
medaka brains were fixed with 4% (w/v) paraformaldehyde (PFA) in phosphate-buffered saline
(PBS) at 4°C for 4 hr and then placed in 30% (w/v) sucrose at 4°C for more than 16 hr. Samples
were embedded in Surgipath FSC 22 (Leica), and 14-μm-thick sections were obtained with a
LEICA CM 1900. For paraffin sections, medaka brains were fixed in 4% (w/v) PFA at 4°C for
16 hr, dehydrated, and embedded in paraffin. Sections with a thickness of 6 to 20 μmwere ob-
tained with a Microm HM 325. For immunohistochemical analyses, the following primary an-
tibodies and a lectin were used: anti-Cathepsin D (Calbiochem, #IM03, 1:200), anti-GFAP
(Sigma-Aldrich, #G3893, 1:1000), anti-LC3 (Santa Cruz, #sc-16755, 1:100), anti-medaka α-syn
(1:2000), anti-p62 (MBL, #PM045, 1:2000), anti-ssDNA (DAKO, #A4506, 1:2000), anti-TH
(Millipore, #MAB318, 1:1000), anti-TPH (Abcam, #ab3907–50, 1:1000), anti-ubiquitin (Santa
Cruz, #sc-8017, 1:50), anti-ubiquitin (DAKO, #Z0458, 1:1000), and biotinylated Lycopersicon
Esculentum (Tomato) Lectin (VECTOR, #B-1175, 5<g/ml). The sections were incubated at
4°C with primary antibodies or lectin for 1 to 3 days and then processed for visualization. As
secondary antibodies, ImmPRESS (VECTOR) was used for diaminobenzidine staining, and
Alexa Fluor-conjugated antibodies (Molecular Probes) were used for immunofluorescence.
Sections were observed with an Olympus CX41 microscope, a BZ-9000 fluorescence micro-
scope (KEYENCE), and an Olympus FV-1000 confocal laser scanning microscope. For confo-
cal microscope images, Pearson's coefficient correlation (r) was calculated using
Olympus software.
Measurement of mRNA in medaka brains
RNA was extracted from medaka brains with Qiazol (QIAGEN) according to the manufactur-
er’s instructions. cDNA was generated with reverse transcription using the PrimeScript RT re-
agent kit (Perfect Real Time) (TaKaRa, #RR037A). The amount of cDNA was quantified with
real-time PCR using LightCycler 480 SYBR Green I Master (Roche, #04887352001) and Roche
LightCycler 480. The following primer sets were used (TNFα: 50-ATTGGAGTGAAAGGCCA-
GAA-30, 50-ACTAATTTGAGACCGCCACG-30; β-actin: 50-TCCACCTTCCAGCAGATGTG-
30, 50-AGCATTTGCGGTGGACGAT-30).
In situ hybridization
The vector including a portion of the medaka APOE cDNA sequence was generously provided
by Dr. H. Mitani (Tokyo University, Tokyo, Japan) (in submission). In situ hybridization was
performed as described[60]. Counterstaining was performed with methyl green (Sigma-
Aldrich, #M8884).
Western blot analyses
For Triton-soluble fractions, samples were homogenized in high-salt buffer containing 1% Tri-
ton X-100 (750 mMNaCl, 5 mM EDTA, 50 mM Tris-HCl, 1% (v/v) Triton X-100, pH 7.5) and
centrifuged at 20,400 ×g at 4°C for 5 min. For SDS-soluble fractions, the pellet was subsequent-
ly sonicated in SDS buffer (50 mM Tris-HCl, 2% SDS, pH 7.4) followed by centrifugation at
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20,400 ×g at 4°C for 5 min. The supernatant was boiled in sample buffer (1% (w/v) SDS, 12.5%
(w/v) glycerol, 0.005% (w/v) bromophenol blue, 2.5% (v/v) 2-mercaptoethanol, 25 mM Tris-
HCl, pH 6.8). Samples were separated on 10%, 12%, or 14% (w/v) gels for SDS-PAGE. Samples
containing 20 μg protein were loaded in each lane for Triton-soluble fractions, and SDS-soluble
fractions were loaded according to the amount of protein in Triton-soluble fractions. Proteins
were transferred to polyvinylidene difluoride membranes with a Trans-Blot SD Semi-Dry
Transfer Cell (Bio-Rad). For detection of medaka α-syn and mouse α-syn, the membranes were
treated with 0.4% (w/v) PFA in PBS for 30 min at room temperature before blocking to prevent
detachment of α-syn from the blotted membranes[61]. For western blot analyses, the following
primary antibodies were used: anti-β-actin (Sigma-Aldrich, #A1978, 1:5000), anti-GFAP
(Sigma-Aldrich, #G3893, 1:1000), anti-LC3 (MBL, #PM036, 1:2000), anti-NSE (DAKO,
#M0873, 1:500), anti-α-syn (BD Transduction, #610787, 1:2000), anti-medaka α-syn (1:10,000),
anti-phosphorylated neurofilament (COVANCE, #smi-31r, 1:1000), anti-p62 (MBL, #PM045,
1:500), anti-TH (Millipore, #MAB318, 1:1000), and anti-ubiquitin (Santa Cruz, #sc-8017, 1:50).
The membranes were incubated with primary antibodies for 1 to 3 days at 4°C, followed by reac-
tion with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz) for 1 hr at
room temperature. Immunoreactive bands were detected with Chemi-Lumi One Super (Nacalai
tesque), and the chemiluminescent signal was detected with Fujifilm LAS-3000. Densitometric
analyses were performed using ImageJ software (National Institutes of Health).
High performance liquid chromatography
To measure the amounts of dopamine, noradrenaline and serotonin in medaka brains, high
performance liquid chromatography was performed as described[60].
Transmission electron microscopy and toluidine blue staining
Medaka brains were fixed with 4% (w/v) PFA and 2% (v/v) glutaraldehyde (Wako, #072–01961)
in 0.1 M phosphate buffer (PB) at 4°C for 16 hr. After rinsing in 0.1 M PB, samples were post-
fixed with 1% (w/v) OsO4 in 0.1 M PB for 2 hr. Then, samples were dehydrated, penetrated with
ethanol and a propylene oxide series, and embedded in Epon. Sections were obtained with an
EMUC6 ultramicrotome (Leica). Sections with a thickness of 1 μmwere used for toluidine blue
staining. Sections with a thickness of 60 to 80 nm were stained with uranyl acetate and lead cit-
rate and observed with a Hitachi H-7650 transmission electron microscope.
Immunoelectron microscopy
Immunoelectron microscopy using ultrathin cryosections was performed as described[62].
Briefly, brains were quickly removed from medaka and immersed in 4% PFA buffered with
0.1 M PB (pH 7.2) at 4°C for 2 hr, washed thoroughly with 7.5% sucrose in 0.1 M PB (pH 7.2),
and embedded in 12% gelatin. The samples were rotated in 2.3 M sucrose in 0.1 M PB overnight
at 4°C, placed on a specimen holder (Leica Microsystems), and quickly plunged into liquid nitro-
gen. Ultrathin cryosections were cut with a Leica UC6/FC6 and UC7/FC7 (Leica Microsystems)
at about—120°C. Sections about 60 nm thick were picked up with a 1:1 mixture of 2%methylcel-
lulose and 2.3 M sucrose and transferred to a nickel grid with a carbon-coated Formvar support-
ing film. The sections were rinsed with PBS containing 0.02 M glycine, treated with 1% bovine
serum albumin in PBS, and incubated overnight at 4°C with rabbit anti-medaka α-syn antibody
(1:30). They were then incubated with goat anti-rabbit IgG conjugated to 10 nm colloidal gold
particles (1:40) (British Biocell International) for 1 hr at room temperature. Immunostained sec-
tions were fixed with 1% glutaraldehyde in PBS. After completion of the labeling, the sections
were embedded in a thin layer of 2%methylcellulose with 0.4% uranyl acetate (pH 4.0), air-
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dried, and observed with a Hitachi H-7100 electron microscope. For control experiments, ultra-
thin sections were reacted only with the gold particle-conjugated secondary antibody.
Statistical analyses
A two-tailed paired Student’s t-test or one-way ANOVA with Tukey’s post-hoc test was used
for analyses. Statistical calculations were performed with Microsoft Excel or GraphPad Prism
Software, Version 5.0.
Supporting Information
S1 Fig. Sequence alignment of GBA. Sequence alignment of human (Homo sapiens), mouse
(Mus musculus), and medaka (Oryzias latipes) GBA protein. Amino acids conserved in two or
three species are outlined. The red outlining indicates the W337X mutation in the GBA non-
sense mutant medaka.
(TIF)
S2 Fig. N-acyl chain distribution of glucocerebroside and galactocerebroside. N-acyl chain
distribution of glucocerebroside and galactocerebroside in medaka brains at 3 months (n = 3–4).
For all analyses, data are the mean ± SEM.
(TIF)
S3 Fig. Periodic acid-Schiff (PAS)-positive abnormal cells in the spleen and kidney of
GBA-/- medaka. PAS staining of medaka spleen and kidney at 3 months. Clusters of abnormal
PAS-positive cells in the spleen and kidney (arrowheads) and high-magnification images (right
panels). Scale bars of right panels, 20 μm. Other scale bars, 50 μm.
(TIF)
S4 Fig. Specificity of medaka α-syn antibody. (A) Sequence alignment of human and medaka
α-syn protein. Conserved amino acids are outlined. The red outlining indicates the epitope of
medaka α-syn antibody. (B) Sequence alignment of medaka α-synuclein (SNCA), β-synuclein
(SNCB), γ-synuclein-a (SNCGa), and γ-synuclein-b (SNCGb). Amino acids conserved in three
or four proteins are outlined. The red outlining indicates the epitope of the medaka α-syn anti-
body. (C) Upper panel: DNA sequences of wild-type α-syn and deleted α-syn. Lower panel: Se-
quence alignment of wild-type α-syn and mutated α-syn. The red outlining indicates the
epitope of the medaka α-syn antibody. (D) Polyacrylamide gel electrophoresis (PAGE) image
of PCR for α-syn. PCR primers were designed to span the deleted region of α-syn, allowing the
genotypes to be distinguished with PAGE. (E) RT-PCR for α-synmRNA. One primer was de-
signed to overlap the deleted region of α-syn. Intact α-synmRNA was not detected in α-syn-/-
medaka. (F) Western blot analysis of α-syn and β-actin. A 14-kDa putative α-syn band was ob-
served only in α-syn+/+ medaka, suggesting the authenticity of the medaka α-syn antibody.
(G) Immunohistochemistry with medaka α-syn antibody. α-syn immunostaining was observed
only in α-syn+/+ medaka. Scale bars, 50 μm. (H) Immunoelectron micrograph of a presynaptic
region with immunogold-labeled α-syn. Left panels: presynaptic area with small synaptic vesi-
cles. Right panels: presynaptic area with large synaptic vesicles. The postsynaptic density is visi-
ble (arrowheads). Scale bars, 200 nm.
(TIF)
S5 Fig. α-syn accumulation was observed in GBA-/- medaka at 2 months, not at 1 month.
α-syn immunohistochemistry at 1 and 2 months after fertilization. α-syn accumulation was
observed in GBA-/- medaka at 2 months (arrowheads). Scale bars, 20 μm.
(TIF)
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S6 Fig. Transmission electron micrographs of neuropil and co-localization analysis of axo-
nal swellings in GBA-/- medaka. (A) Transmission electron micrographs of neuropil. Left and
middle panels: Neuropil of a GBA+/+ and a GBA-/- medaka, respectively. Swellings of both mye-
linated (arrowheads) and unmyelinated (outlined by dashed lines) axons were found in GBA-/-
medaka, which contain vacuoles and electron-dense bodies. Scale bars, 2 μm. Right panels:
High-magnification images of swellings of myelinated and unmyelinated axons (lower and
upper panels, respectively). Scale bars, 500 nm. (B) Co-localization analysis for different mark-
ers in axonal swellings of GBA-/- medaka. The correlation between LC3, ubiquitin, and α-syn
signals are shown as the pixel scatter diagrams and a graph (n = 6). For all analyses, data are
the mean ± SEM.
(TIF)
S7 Fig. Analyses of GBA+/−medaka at 12 months. (A) α-syn immunohistochemistry at 12
months. α-syn accumulation was not observed in GBA+/- medaka. Scale bars, 20 μm. (B) West-
ern blot analysis of α-syn and β-actin (n = 5–6). (C) Numbers of TH-positive neurons in the
middle diencephalon and TH-positive neurons in the locus coeruleus at 12 months (n = 4).
(D) Total swimming distance at 12 months (n = 12). (E) Amounts of dopamine, noradrenaline,
and serotonin in the brains at 12 months measured with high performance liquid chromatog-
raphy. All values are expressed as the amount (μg) per protein (mg) (n = 12). For all analyses,
data are the mean ± SEM. A two-tailed paired Student’s t-test was used to determine the
statistical significance.
(TIF)
S8 Fig. Localization and co-localization analyses in the brains of GBA-/- medaka. (A) Dou-
ble immunostaining in GBA-/- medaka at 3 months. Upper panels: NeuN (green), GFAP
(green), or LEL (green) and p62 (red). Lower panels: NeuN (green), GFAP (green), or LEL
(green) and ubiquitin (red). Nuclei were visualized with DAPI (blue). p62- and Ubiquitin-
positive aggregates were localized only in NeuN-positive neurons, but not in GFAP-positive ra-
dial glial cells or LEL-positive microglia. Scale bars, 20 μm. (B) Co-localization analysis for dif-
ferent markers in the brains of GBA-/- medaka. The correlation between LC3, ubiquitin, and
α-syn signals are shown as the pixel scatter diagrams and a graph (n = 6). For all analyses, data
are the mean ± SEM.
(TIF)
S9 Fig. Transgenic expression of GBA reversed the pathological phenotypes of GBA-/- me-
daka. (A) Transgenic construct used to establish GBA transgenic medaka. (B) GCase activity in
the brains of each Tg(GAP-43:GBA);GBA-/- lines (described as Tg-line No.;GBA-/- in the figure)
at 3 months (n = 5–6). (C) Total swimming distance during 3 min in GBA+/+, GBA-/-, and Tg
(GAP-43:GBA)line3;GBA-/- medaka (n = 8, p< 0.05). (D) Hematoxylin and eosin staining,
APOE in situ hybridization, and p62 and α-syn immunohistochemistry of Tg(GAP-43:GBA)
line3;GBA-/- medaka showed no major abnormalities. Scale bars, 100 μm, 50 μm, 10 μm,
20 μm, respectively. For all analyses, data are the mean ± SEM.
(TIF)
S1 Movie. Swimming movement of GBA+/+ medaka at 2 months.
(MP4)
S2 Movie. Swimming movement of GBA-/- medaka at 2 months.
(MP4)
S3 Movie. Swimming movement of Tg(GAP-43:GBA)line3;GBA-/- medaka at 2 months.
(MP4)
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